Sign Up Today and Learn More About ArsenalBio Stock
Invest in or calculate the value of your shares in ArsenalBio or other pre-IPO companies through EquityZen's platform.
ArsenalBio Stock (ARSB)
ArsenalBio is a programmable cell therapy company.
About ArsenalBio Stock
Founded
2019
Headquarters
South San Francisco, CA, US
Industries
Software, Artificial Intelligence, Data and Analytics
ArsenalBio is building a programmable cell therapy company to create highly effective and accessible immune cell therapies to impact outcomes for a much broader number of patients, initially those with cancer. Founded in 2019, ArsenalBio is focused on integrating technologies such as CRISPR-based genome engineering, scaled and high throughput target identification, synthetic biology, and machine learning to advance a new paradigm to discover and develop in immune cell therapies. With its programmable and computationally driven approach, ArsenalBio aspires to evolve critical metrics of success for immune cell therapies, including enhanced and broader efficacy, increased patient safety, reduced provider costs, and expanded market access.
ArsenalBio Press Mentions
Stay in the know about the latest news on ArsenalBio
The show’s not over: 2024 sees big boost to AI investment
venturebeat • Nov 02, 2024
North American Startup Funding Weakened In Q3 As Largest Deal Took Longer To Close
news • Oct 04, 2024
The 10 Biggest Rounds Of September: Safe Superintelligence’s $1B Raise Reigns Supreme
news • Oct 01, 2024
The Week’s 10 Biggest Funding Rounds: Safe Superintelligence Leads With Massive $1B Raise
news • Sep 06, 2024
ArsenalBio raises $325m for programmable CAR-T platform
pharmaphorum • Sep 06, 2024
ArsenalBio Management
Leadership team at ArsenalBio
Chief Technology Officer
Tarjei Mikkelsen
Chief Scientific Officer
Jane Grogan
Join now and verify your accreditation status to gain access to:
- ArsenalBio current valuation
- ArsenalBio stock price
- Available deals in ArsenalBio and all other companies
- Deal offering documents
- EquityZen's proprietary data and insights, including
- Cap tables, which include funding history by Share Class and Liquidity Preferences
- Company Highlights
- Business Model
- Risk Factors
How to invest in ArsenalBio stock?
Accredited investors can buy pre-IPO stock in companies like ArsenalBio through EquityZen funds. These investments are made available by existing ArsenalBio shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell ArsenalBio stock?
Shareholders can sell their ArsenalBio stock through EquityZen's private company marketplace. EquityZen's network includes over 330K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 43K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
